Cue Biopharma, Inc. (CUE)

Over the past six months, Cue Biopharma's stock price has significantly declined, reaching $0.30 as of December 30, 2025, a 72.26% decrease from $1.09 on December 31, 2024. Key events impacting the stock price include a proposed public offering of common stock and warrants in December 2025, which led to a 30% plunge in shares, Q3 2025 financial results reporting a loss and lagging revenue estimates, and analyst rating changes with an overall consensus rating of "Sell" and a reduced 12-month price target.

Based on historical stock price data, there is some indication of demand seasonality for Cue Biopharma's stock. January has historically shown the highest probability of a positive return, while March has the lowest. The seasonal timeframe for CUE is inline with the broader Healthcare sector's period of seasonal strength, which typically runs from April 25 to December 4. The search results do not provide specific information on the demand seasonality for Cue Biopharma's products and services.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing injectable biologic drugs that modulate the human immune system to treat cancers and autoimmune disorders. Their Immuno-STAT™ platform selectively engages and modulates disease-relevant T cells. The CUE-100 series is designed to activate tumor-specific T cells, with CUE-101 in Phase 1b clinical trials for HPV16-positive recurrent metastatic head and neck squamous cell carcinoma and CUE-102 in Phase 1b clinical trials for WT1+ cancers. The CUE-400 series aims to enhance regulatory T cells, with CUE-401 in preclinical trials for autoimmune conditions. The CUE-500 series is designed to redirect antiviral T cells to eliminate pathogenic cells, with CUE-501 in preclinical trials for autoimmune disease. The company also provides clinical trials and research services.

Cue Biopharma, Inc. is headquartered in Boston, Massachusetts, with research and manufacturing activities primarily in the United States. They have collaboration agreements with LG Chem, Ltd. for CUE-101 and CUE-102, Ono Pharmaceutical Co., Ltd for CUE-401, and a license agreement with Albert Einstein College of Medicine.

Cue Biopharma's reputation can be inferred from its clinical progress, collaborations, and analyst sentiment. Positive aspects include promising results in clinical studies, particularly with CUE-101 in combination with Keytruda, and collaborations with companies like LG Chem and Ono Pharmaceuticals. Negative aspects include a significant decrease in projected enterprise value, reduced price targets by analysts, and a recent public offering that led to a sharp decline in stock price due to dilution concerns.

Cue Biopharma is owned by a mix of institutional shareholders (14.49% to 22.94%), insiders (0.25% to 12.26%), and retail investors (69.88% to 77.91%). Major institutional owners include Bleichroeder LP, Catalytic Wealth RIA, LLC, Vanguard Group Inc, Geode Capital Management, Llc, Boothbay Fund Management, Llc and BlackRock, Inc.. Cameron Gray is the largest individual shareholder, owning 1.63% of the company. Insider buying has been observed in the past three months, with Pasha Sarraf, Chairman of the Board, buying 323,857 shares in December 2025.